Literature DB >> 7522528

Recent advances in hepatic transplantation at the University of Pittsburgh.

K Abu-Elmagd1, O Bronsther, A Jain, W Irish, H Ramos, I R Marino, F Dodson, R Selby, H Doyle, H Furukawa.   

Abstract

FK506 undoubtedly improved the survival advantage of hepatic allotransplantation. Hepatic-intestinal and multivisceral transplantation has also become a feasible therapy for patients with combined intestinal and liver failure. With better understanding of the immunologic and metabolic aspects of allo- and xenotransplantation, further clinical attempts to transplant animal organs to humans may be considered with the hope for a better outcome in the very near future.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7522528      PMCID: PMC3032438     

Source DB:  PubMed          Journal:  Clin Transpl        ISSN: 0890-9016


  48 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

2.  Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings.

Authors: 
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Pharmacokinetics of FK 506: preclinical and clinical studies.

Authors:  R Venkataramanan; A Jain; E Cadoff; V Warty; K Iwasaki; K Nagase; A Krajack; O Imventarza; S Todo; J J Fung
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

4.  A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

Authors:  J Fung; K Abu-Elmagd; A Jain; R Gordon; A Tzakis; S Todo; S Takaya; M Alessiani; A Demetris; O Bronster
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

5.  Infectious complications of pediatric liver transplantation under FK 506.

Authors:  M Green; A Tzakis; J Reyes; B Nour; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  Infections in adult liver transplant patients under FK 506 immunosuppression.

Authors:  M Alessiani; S Kusne; M Martin; A Jain; K Abu-Elmagd; J Moser; S Todo; J Fung; T Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

7.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

Authors:  R Venkataramanan; A Jain; V W Warty; K Abu-Elmagd; H Furakawa; O Imventarza; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

8.  Liver transplantation under cyclosporine: a decade of experience.

Authors:  R D Gordon; S Todo; A G Tzakis; J J Fung; A Stieber; S M Staschak; S Iwatsuki; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

9.  The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver.

Authors:  K Abu-Elmagd; J J Fung; M Alessiani; A Jain; R Venkataramanan; V S Warty; S Takaya; S Todo; W D Shannon; T E Starzl
Journal:  Transplantation       Date:  1991-07       Impact factor: 4.939

10.  Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1.

Authors:  S Takaya; Y Iwaki; T E Starzl
Journal:  Transplantation       Date:  1992-11       Impact factor: 4.939

View more
  1 in total

1.  Causes of late mortality in pediatric liver transplant recipients.

Authors:  D L Sudan; B W Shaw; A N Langnas
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.